Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 393,496 | 288,669 | 53,917 | 9,202 | 7,942 |
| Cost of Goods | 47,892 | 48,049 | 12,788 | 4,168 | N/A |
| Gross Profit | 345,604 | 240,620 | 41,129 | 5,034 | 7,942 |
| Operating Expenses | 648,145 | 733,701 | 633,844 | 539,717 | 385,610 |
| Operating Income | -301,649 | -493,032 | -591,927 | -534,515 | -377,667 |
| Interest Expense | 108,239 | 47,692 | 53,193 | 4,627 | 92,346 |
| Other Income | 6,005 | 27,558 | 36,332 | 84,898 | -8,809 |
| Pre-tax Income | -403,884 | -513,166 | -608,788 | -454,244 | -478,822 |
| Income Tax | 5,241 | 7,904 | 5,665 | -434 | -250 |
| Net Income Continuous | -409,125 | -521,070 | -614,453 | -453,810 | -478,572 |
| Net Income | $-409,125 | $-521,070 | $-614,453 | $-453,810 | $-478,572 |
| EPS Basic Total Ops | -7.07 | -9.25 | -10.96 | -8.28 | -9.46 |
| EPS Basic Continuous Ops | -7.07 | -9.26 | -10.96 | -8.29 | -9.45 |
| EPS Diluted Total Ops | -7.07 | -9.25 | -10.96 | -8.28 | -9.46 |
| EPS Diluted Continuous Ops | -7.07 | -9.26 | -10.96 | -8.29 | -9.45 |
| EPS Diluted Before Non-Recurring Items | -7.07 | -9.24 | -10.96 | -8.28 | -9.46 |
| EBITDA(a) | $-282,481 | $-472,565 | $-573,007 | $-516,306 | $-366,875 |